Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
Squamous Cell Carcinoma of Head and Neck
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
Carcinoma, Non-Small Cell Lung

Interventions: Drug: sigvotatug vedotin

First Posted Date: 2024-08-12

Last Posted Date: 2025-06-10

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 6

Registration Number: NCT06549816

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Union Hospital Affiliated to Tongji Medical College,Huazhong University of science and Technology, Wuhan City, Hubei, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

A Study of SGN-MesoC2 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Ovarian Neoplasms
Pancreatic Adenocarcinoma
Colorectal Neoplasms
Mesothelioma
Other Solid Tumors
Endometrial

Interventions: Drug: PF-08052666

First Posted Date: 2024-06-20

Last Posted Date: 2025-06-19

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 365

Registration Number: NCT06466187

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
The University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 16 locations

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

First Posted Date: 2024-04-12

Last Posted Date: 2025-06-17

Lead Sponsor: Seagen Inc.

Registration Number: NCT06362590

A safety study of SGN-35C in adults with advanced cancers

Phase 1

Recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Lymphoma, T-Cell, Peripheral
Lymphoma, Large-Cell, Anaplastic

Interventions: Drug: PF-08046044/SGN-35C

First Posted Date: 2024-07-30

Last Posted Date: 2025-04-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 48

Registration Number: 2023-505813-26-00

Locations: 🇩🇰
Rigshospitalet, Copenhagen Oe, Denmark
🇪🇸
Hospital Universitari Vall D Hebron, Barcelona, Spain
🇩🇪
Charite Universitaetsmedizin Berlin KöR, Berlin, Germany

and more 5 locations

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2

Recruiting

Conditions: Breast Neoplasms
Gastroesophageal Junction Adenocarcinoma
HER2 Low Breast Neoplasms
HER2 Positive Breast Neoplasms
Stomach Neoplasms
Triple Negative Breast Neoplasms
Metastatic Breast Cancer
Metastatic Gastric Cancer
Advanced Breast Cancer
Advanced Gastric Cancer

Interventions: Drug: disitamab vedotin
Drug: tucatinib

First Posted Date: 2023-12-06

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 172

Registration Number: NCT06157892

Locations: 🇺🇸
Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
🇺🇸
Banner-University Medical Center Tucson Campus, Tucson, Arizona, United States
🇺🇸
The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal, Tucson, Arizona, United States

and more 115 locations

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Stomach Neoplasms
Small Cell Lung Carcinoma
Gastroesophageal Junction Adenocarcinoma
Colorectal Neoplasms
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: PF-08046050
Drug: bevacizumab

First Posted Date: 2023-11-14

Last Posted Date: 2025-06-11

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 494

Registration Number: NCT06131840

Locations: 🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States

and more 25 locations

A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

Phase 1

Recruiting

Conditions: Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell, Cutaneous
Hodgkin Disease
Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: PF-08046045

First Posted Date: 2023-11-07

Last Posted Date: 2025-06-12

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 150

Registration Number: NCT06120504

Locations: 🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
University of Miami Hospital and Clinics - Lennar, Coral Gables, Florida, United States
🇺🇸
University of Miami Hospital And Clinics, Miami, Florida, United States

and more 33 locations

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: sigvotatug vedotin
Drug: docetaxel

First Posted Date: 2023-08-25

Last Posted Date: 2025-06-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 670

Registration Number: NCT06012435

Locations: 🇨🇭
Inselspital, Bern, Other, Switzerland
🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸
Arizona Oncology Associates, Prescott, Arizona, United States

and more 261 locations

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Ovarian Neoplasms
Endometrial Neoplasms
Head and Neck Neoplasms

Interventions: Drug: disitamab vedotin

First Posted Date: 2023-08-21

Last Posted Date: 2025-06-29

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 119

Registration Number: NCT06003231

Locations: 🇺🇸
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Scottsdale, Arizona, United States
🇺🇸
Valkyrie Clinical Trials(Additional Suite), Los Angeles, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 79 locations

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Colorectal Neoplasms
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: SGN-EGFRd2
Drug: PF-08046052

First Posted Date: 2023-08-09

Last Posted Date: 2025-06-19

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 290

Registration Number: NCT05983133

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy